This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Pierre Fabre Medicament S.A.
Drug Names(s): vinflunine ditartrate
Description: Javlor is a bi-fluorinated Vinca alkaloid derivative of vinorelbine that targets the microtubule network to induce mitotic block and apoptosis.
Deal Structure: In April 2004, Bristol-Myers Squibb and Pierre Fabre Medicament announced that they entered into an agreement to develop and commercialize Javlor. Under the terms of the agreement, Bristol-Myers Squibb will receive an exclusive license to Javlor in the United States, Canada, Japan, Korea, and select Southeast Asian markets. Financial terms of the deal were not disclosed. Pierre Fabre Medicament will be responsible for the development and marketing of Javlor in all other countries, including Europe.
In November 2007, Bristol-Myers Squibb and Pierre Fabre Medicament terminated their license agreement for the development of vinflunine. The companies have jointly decided that all rights licensed to Bristol-Myers Squibb for vinflunine will be returned to Pierre Fabre Medicament.
Additional information available to subscribers only: